A user has been using dutasteride, RU58841, minoxidil, and ketoconazole for 2 years with no progress and worsening hair recession. They seek advice on how to proceed.
Finasteride is not linked to a 60% risk of persistent sexual dysfunction; this figure applies only to those already experiencing sexual issues. Most users do not have side effects, and the study's methodology is criticized for selection bias.
PP405 is a new topical treatment for hair loss, showing promise in trials but still requires finasteride for maintenance. There is skepticism about its effectiveness and safety, with concerns about needing finasteride to maintain results.
The post discusses speeding up verteporfin trials for hair loss treatment. The original poster, involved in the trials, requests help in crowdsourcing doctor emails to spread awareness and gather more support for the trials.
The user has been taking finasteride daily for almost two years, starting at age 25, and has experienced stabilization and minor regrowth in hair loss without significant side effects, except for increased urination. They encourage others dealing with hair loss to consider treatment options and not be discouraged by varying response times.
A user shared their baseline bloodwork results before starting Finasteride 1mg every other day, seeking comparison with others who have done similar tests. They are interested in any changes observed after beginning the treatment.
A user shared their 1 and 2-year hair progress using finasteride only, showing significant improvement. They experienced some initial side effects but found the treatment effective and regret not starting earlier.
The user has been using finasteride three times a week for a year and plans to add minoxidil to improve hair regrowth. They are seeking opinions on any noticeable new hair growth.
The user shared progress pictures showing hair improvement after using 5% topical minoxidil for two years and 1mg finasteride for one year. The user also used tretinoin and trifarotene as part of their routine.
Hair/scalp cloning for unlimited transplants is likely a decade away, with prior transplants not significantly affecting future options. Advances in AI and research in wound-induced hair neogenesis are promising, but infrastructure and technology constraints remain challenges.
The user shared progress on hair loss treatment, starting finasteride in 2018 and adding minoxidil in November 2023, with significant improvement. The user started treatment at age 31.
The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
Kintor's Phase II U.S. trials for pyrilutamide and the process of pharmaceutical drugs coming to market, with a reply from someone who has just ordered 500mg of Pyrilutamide to start their own phase trials.
Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.
A user shared their experience with microneedling and minoxidil for hair loss, avoiding finasteride due to concerns about systemic hormone effects. They reported slight hair regrowth after one month and plan to continue the regimen, noting improvements in skin sensitivity and managing dandruff with anti-dandruff shampoo.
Long term Finasteride users and whether or not they have noticed improvements after two years of use, with other treatments such as Minoxidil and dermarolling also discussed. Some replies suggest that improvement is possible even beyond the two year mark while others caution against believing studies backed by the Post-Finasteride Foundation.
The user experienced significant hair regrowth using finasteride, topical minoxidil, derma stamping, and ketoconazole shampoo, starting treatment at age 19. They reported no side effects and emphasized the importance of starting treatment early.
Two twins who used Minoxidil, finasteride and dermarollers to treat their androgenic alopecia over a 10 month time period. The user is providing details on the process they use for dermarolling.
The conversation discusses a five-year study on dutasteride, a medication for male hair loss. The study found that 89.9% of patients saw improvement or prevention of hair loss progression, with varying success rates based on different balding patterns. Side effects were mostly sexual and decreased over time. Dutasteride was concluded to be a long-term, safe, and effective treatment for male hair loss.
Researching the release of phase 2 trials for pyrilutamide, a potential hair loss treatment, and discussing other treatments such as Minoxidil, Finasteride, and RU58841.
Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.
A trial of verteporfin for hair regeneration, with pictures comparing the original and current status, as well as links to other resources discussing the efficacy of this treatment in combination with Minoxidil, Finasteride, and RU58841.
The conversation is about gathering serum DHT data from individuals taking dutasteride to investigate its efficacy, especially in cases with unexpectedly low DHT reduction. The aim is to explore potential genetic factors affecting drug metabolism.
The user is using finasteride 1mg daily for one month and ketoconazole three times a week for three months. They are comparing hair progress with photos from December 2025 and March 2026.
A 28-year-old male using only oral finasteride 1mg since May 15, 2024, reports no side effects and significant hair improvement. He plans to continue finasteride for three more months and is considering adding D3+K2 drops, zinc, folate, and magnesium glycinate.
The user noticed receding hair at the temples and is considering starting finasteride and minoxidil to thicken the hairline. They plan to consult a doctor and begin treatment soon.
Hair loss treatments like GT20029, pyrilutamide, and Follica show promise in 2022. Phase 1 and 2 trials are underway, and new hair growth studies have been published.
Verteporfin shows promise in donor hair regeneration after 84 days. Combining Finasteride, Minoxidil, and Pyrilutamide with unlimited hair transplants is seen as a potential near-cure for hair loss.
Han Bio plans to start Phase 1 clinical trials for a hair growth treatment in 2027 after successful results in mice. Many users express skepticism about the effectiveness of treatments that work on mice but not on humans, and discuss existing treatments like finasteride and minoxidil.